Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Chromadex Corp CS (CDXC)

Chromadex Corp CS (CDXC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
New Study Demonstrates a Unique Role of Nicotinamide Riboside Over Other NAD Precursors

ChromaDex Corp. (NASDAQ:CDXC) announced today that the results of a preclinical study conducted by Nestle were published last month in the journal Nature Communications, a peer-reviewed open access scientific...

CDXC : 3.33 (-1.77%)
ChromaDex Statement Regarding the October 9th Order in the Central District of California Litigation

ChromaDex Corp. (NASDAQ:CDXC) issued the following statement.

CDXC : 3.33 (-1.77%)
Humanitarian Grant Awarded for Preclinical Study on the Impact of NAD Precursor Vitamins on Milk Bioactive Production and Brain Development in Rodents

Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa, receives a research grant from the Bill & Melinda Gates Foundation to study the effects of NAD-boosting...

CDXC : 3.33 (-1.77%)
ChromaDex to Present at the 5th Annual B. Riley FBR Consumer and Media Conference

ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 5 Annual B. Riley FBR Consumer and Media Conference...

CDXC : 3.33 (-1.77%)
ChromaDex Announces $7 Million Private Placement of Common Stock

ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a securities purchase agreement for the sale of $7.0 million of its common stock in a private placement. The private placement was...

CDXC : 3.33 (-1.77%)
ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 15.38% and 2.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

CDXC : 3.33 (-1.77%)
ChromaDex Receives Positive Opinion on Nicotinamide Riboside as a Novel Food from the World-Leading European Food Safety Authority (EFSA)

ChromaDex Corp. (NASDAQ:CDXC) today announced that the European Food Safety Authority (EFSA) has issued a positive opinion on Nicotinamide Riboside (NR) as a novel food ingredient for use in a food supplement...

CDXC : 3.33 (-1.77%)
ChromaDex Corporation Reports Second Quarter 2019 Financial Results

Second Quarter 2019 Highlights vs. Second Quarter 2018

CDXC : 3.33 (-1.77%)
ChromaDex Adds Top Talent to its Leadership Team

ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today three strategic hires to its executive team.

CDXC : 3.33 (-1.77%)
ChromaDex to Report Second Quarter 2019 Financial Results on Wednesday, August 7, 2019

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., August 7, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the second quarter ended June 30, 2019....

CDXC : 3.33 (-1.77%)
TRU NIAGEN(R) Expands Canadian Retail Footprint with Distribution at Whole Foods Ontario Locations

ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product, Tru Niagen (nicotinamide riboside) is now available in all seven Whole Foods Market locations across Ontario, in addition to...

CDXC : 3.33 (-1.77%)
ChromaDex Appoints Scripps Research Professor of Molecular Medicine, Brunie H. Felding, PhD, to the Scientific Advisory Board

ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed Brunie H. Felding, Ph.D., Associate Professor, Department of Molecular Medicine, Scripps Research Institute, California Campus, to the Scientific...

CDXC : 3.33 (-1.77%)
Newly Published Nicotinamide Riboside Study Further Demonstrates Safety of Sustained Niagen Supplementation and Optimal Dosing Levels

ChromaDex Corp. (NASDAQ:CDXC) announced today that the results of its latest clinical study were published Friday in the journal Scientific Reports. The largest trial of nicotinamide riboside (NR) published...

CDXC : 3.33 (-1.77%)
TRU NIAGEN(R) Awarded 'Ingredient of the Year: Healthy Aging' by NutraIngredients-USA

ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product, Tru Niagen(R) (nicotinamide riboside) received the 'Ingredient of the Year: Healthy Aging' award at the NutraIngredients-USA...

CDXC : 3.33 (-1.77%)
ChromaDex to Present at the 20th Annual B. Riley FBR Investor Conference

ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 20 Annual B. Riley FBR Investor Conference at the...

CDXC : 3.33 (-1.77%)
ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 0.00% and 2.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

CDXC : 3.33 (-1.77%)
ChromaDex Corporation Reports First Quarter 2019 Financial Results

- First Quarter 2019 Net Revenues Increased by 53% to $10.0 Million -

CDXC : 3.33 (-1.77%)
ChromaDex Announces $10 Million Issuance of Convertible Notes

ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible notes in a private placement. The transaction was led by international...

CDXC : 3.33 (-1.77%)
ChromaDex to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 9, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2019....

CDXC : 3.33 (-1.77%)
ChromaDex Furthers TRU NIAGEN(R) Global Expansion in Canada with WELL Health Technologies

ChromaDex Corp. (NASDAQ:CDXC) announced today a new distribution partnership for TRU NIAGEN(R) with Vancouver-based WELL Health Technologies Corp. (TSX.V: WELL) who intends on distributing TRU NIAGEN(R)...

WELL.VN : 1.330 (+0.76%)
CDXC : 3.33 (-1.77%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +4.89 , AIZ +0.49 , SBAC +7.10 , SO -0.03 , WELL +0.16
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar